Haleon plc
Haleon plc (HLN) Stock Overview
Explore Haleon plc’s financial performance, market position, analyst ratings, and future outlook.
HLN Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Haleon plc (HLN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $10.86.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 24.19 and a market capitalization of 46.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Mr. Brian James McNamara
24,561
Building 5, Weybridge
2022